Abramson Cancer Center at Penn Medicine
pennmedicine.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
453
Active
137
Phase 3
1
Total enrollment
491,482
Pipeline matrix
Showing 40 of 62 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | 15 | ||||
| Ipilimumab | — | — | — | — | 6 | ||
| Hydroxychloroquine | — | — | — | 13 | |||
| Nivolumab | — | — | — | 7 | |||
| Paclitaxel | — | — | — | — | 5 | ||
| Carboplatin | — | — | — | — | 3 | ||
| Niraparib | — | — | — | — | — | 2 | |
| Oxaliplatin | — | — | — | — | 5 | ||
| docetaxel | — | — | — | — | — | 2 | |
| Palbociclib | — | — | — | — | 2 | ||
| HCQ | — | — | — | — | — | 2 | |
| filgrastim | — | — | — | — | — | 2 | |
| Everolimus | — | — | — | — | 2 | ||
| Leucovorin | — | — | — | — | — | 2 | |
| 5-fluorouracil | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | — | 2 | |
| Avelumab | — | — | — | — | 2 | ||
| Epcoritamab | — | — | — | — | — | 1 | |
| mosunetuzumab | — | — | — | — | — | 1 | |
| glofitamab | — | — | — | — | — | 1 | |
| obinutuzumab | — | — | — | — | — | 1 | |
| FOLFIRI | — | — | — | — | — | 1 | |
| Photofrin 2.0 mg/kg | — | — | — | — | — | 1 | |
| Capecitabine Oral Product | — | — | — | — | — | 1 | |
| Temozolomide Oral Product | — | — | — | — | — | 1 | |
| transarterial radioembolization | — | — | — | — | — | 1 | |
| ATRN-119 | — | — | — | — | — | 1 | |
| Ramucirumab | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| XmAb20717 | — | — | — | — | — | 1 | |
| RP2 | — | — | — | — | — | 1 | |
| Pegfilgrastim | — | — | — | — | — | 1 | |
| Odetiglucan | — | — | — | — | — | 1 | |
| 18F-Fluoroestradiol | — | — | — | — | — | 1 | |
| [18F]FluorThanatrace | — | — | — | 5 | |||
| Abraxane | — | — | — | — | 6 | ||
| [F-18]-FAPI-74 | — | — | — | — | — | 1 | |
| SBRT + atezolizumab and bevacizumab | — | — | — | — | — | 1 | |
| Vancomycin 125mg | — | — | — | — | — | 1 |
22 more active programs hidden
Next readouts
- 2022-05-17
- 2024-12-01
- 2026-01
- 2026-06
- 2026-06-30
- 2026-08
- 2026-08
- 2026-09-30
- 2026-10
- 2026-10-01
Top conditions
- Breast Cancer50
- Cancer22
- Lung Cancer18
- Prostate Cancer16
- Ovarian Cancer13
- Head and Neck Cancer11
- Colorectal Cancer11
- Cardiotoxicity10
Frequently asked questions about Abramson Cancer Center at Penn Medicine
- How many clinical trials does Abramson Cancer Center at Penn Medicine have on ClinicalTrials.gov?
- Abramson Cancer Center at Penn Medicine is listed as the lead sponsor on 453 clinical trials in ClinicalTrials.gov, 137 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Abramson Cancer Center at Penn Medicine's trials are in Phase 3?
- 1 of Abramson Cancer Center at Penn Medicine's trials are in Phase 3, spread across 62 active drug programs.
- What therapeutic areas does Abramson Cancer Center at Penn Medicine focus on?
- Abramson Cancer Center at Penn Medicine's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Ovarian Cancer.
- When are Abramson Cancer Center at Penn Medicine's next clinical trial readouts?
- Abramson Cancer Center at Penn Medicine has 10 upcoming primary-completion readouts tracked here; the soonest is “CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer”, expected around 2022-05-17.